HCM
DMAAR

Highbridge Capital Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Highbridge Capital Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62.6K Buy
1,044,319
+20,207
+2% +$2.14K ﹤0.01% 270
2025
Q4 		$162K Buy
1,024,112
+40,512
+4% +$7.86K 0.01% 166
2025
Q3 		$214K Buy
983,600
+133,600
+16% +$24.8K 0.01% 142
2025
Q2 		$106K Hold
850,000
– – ﹤0.01% 183
2025
Q1 		$111K Buy
+850,000
New +$119K ﹤0.01% 149

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Highbridge Capital Management's DMAAR Position: Q1 2026 in Review

Highbridge Capital Management increased its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 2% in Q1 2026, buying an estimated $2.14K and bringing the position to 1,044,319 shares worth $62.6K. The position accounts for ﹤0.01% of the portfolio, ranked #270.

Highbridge Capital Management first reported a position in DMAAR in Q1 2025 and has held it in 5 quarters since. The position peaked at $214K in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Highbridge Capital Management held 1,044,319 shares of Drugs Made In America Acquisition Corp Rights worth $62.6K as of Q1 2026.
  • Highbridge Capital Management bought 20,207 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $2.14K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Highbridge Capital Management's portfolio in Q1 2026, its #270 holding.
  • Highbridge Capital Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 5 quarters since.
  • Highbridge Capital Management's Drugs Made In America Acquisition Corp Rights position peaked at $214K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Highbridge Capital Management's 13F filing for Q1 2026, filed 15 May 2026.